Are Medical Stocks Lagging Actinium Pharmaceuticals (ATNM) This Year?

Core Viewpoint - Actinium Pharmaceuticals (ATNM) has shown strong year-to-date performance, significantly outperforming the average returns of the Medical sector [1][4]. Company Performance - Actinium Pharmaceuticals has returned approximately 34.1% since the beginning of the calendar year, while the average return for stocks in the Medical sector is about 7% [4]. - The Zacks Consensus Estimate for ATNM's full-year earnings has increased by 11.7% over the past quarter, indicating improved analyst sentiment and a more positive earnings outlook [4]. Industry Context - Actinium Pharmaceuticals is part of the Medical - Drugs industry, which consists of 146 individual companies and currently ranks 70 in the Zacks Industry Rank [6]. - Stocks within the Medical - Drugs industry have gained about 7.1% year-to-date, showing that ATNM is performing better than its peers in this specific industry [6]. Comparison with Peers - Collegium Pharmaceutical (COLL), another stock in the Medical sector, has outperformed the sector with a year-to-date return of 70.6% and has a Zacks Rank of 1 (Strong Buy) [5]. - The consensus EPS estimate for Collegium Pharmaceutical has increased by 9.1% over the past three months, reflecting a positive outlook similar to that of Actinium Pharmaceuticals [5].